Selected References
- Alsebayel MM, et al. 2018. Congenital esophageal atresia and microtia in a newborn secondary to mycophenolate mofeil exposure during pregnancy: A case report and review of the literature. Am J Case Rep 3(19) 523-526.
- Boyle S, et al. 2021.Pregnancy following heart transplantation: A single centre case series and review of the literature. Heart Lung Circ.;30:144–53.
- Coscia LA, et al. 2015. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet 4(2):42-55.
- Egeberg A, et al 2017 Birth outcomes in children fathered by men treated with immunosuppressant drugs before conception-A Danish population-based cohort study. J Invest Dermatol.Aug;137(8):1790-1792. doi: 10.1016/j.jid.2017.03.030. Epub 2017 Apr 19. PMID: 28433544
- Hoeltzenbein M, et al. 2012. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 158A(3):588-596.
- Jones A, et al. 2013. Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products. 23(2)153-157.
- Kim M, Rostas S, and Gabardi S. 2013. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant 13(6):1383-1389.
- King RW, et al. 2017. Pregnancy outcomes related to mycophenolate exposure in female kidney transplant recipients. Am J Transplant 17(1)151-160.
- Martin MC et al. 2014. Esophageal atresia and prenatal exposure to mycophenolate. Reprod Toxicol 50:117-121, 2014.
- Martin- Moreno PL, et al 2021. Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study. Clin Transplant 35(5): e14256. PMID: 33599030. DOI: 10.1111/ctr.14256.
- Midtvedt K, et al. 2017. Exposure to mycophenolate and fatherhood. Transplantation 101(7) e214-217.
- Perez-Aytes A, et al. 2017. Mycophenolate mofetil embryopathy: A newly recognized teratogenic syndrome. Eur J Med Genet 60(1):16-21.
- Sifontis NM, et al. 2006. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82:1698-1702.
